XML 15 R2.htm IDEA: XBRL DOCUMENT v3.22.2.2
Consolidated Balance Sheets - USD ($)
$ in Thousands
Jul. 31, 2022
Jul. 31, 2021
CURRENT ASSETS    
Cash and cash equivalents $ 26,537 $ 7,854
Restricted cash 5,000
Available-for-sale securities 36,698
Interest receivable 140
Trade accounts receivable, net of allowance for doubtful accounts of $197 and $193 at July 31, 2022 and July 31, 2021, respectively 157 235
Due from Cornerstone Pharmaceuticals, net of allowance for losses on related party receivables of $720 and $0 at July 31, 2022 and July 31, 2021, respectively 600
Prepaid expenses and other current assets 4,621 1,075
Assets held-for-sale 40,194
Total current assets 108,347 14,764
Property and equipment, net 1,770 1,840
Equity investment – RP Finance LLC 575
Due from RP Finance LLC, net of allowance for losses on related party receivables of $9,375 and $0 at July 31, 2022 and July 31, 2021, respectively 7,500
Investments – Cornerstone Pharmaceuticals 79,141
Investments – Other Pharmaceuticals 477 477
Investments – Hedge Funds 4,764 5,268
In-process research and development and patents 1,575 1,575
Other assets 1,387 1,517
Non-current assets held-for-sale   41,398
TOTAL ASSETS 118,320 154,055
CURRENT LIABILITIES    
Trade accounts payable 564 1,160
Accrued expenses 1,875 1,227
Other current liabilities 3,518 252
Due to related parties 69 136
Note payable, net of debt issuance costs, held-for-sale 15,000 14,528
Total current liabilities 21,026 17,303
Other liabilities 88 48
TOTAL LIABILITIES 21,114 17,351
COMMITMENTS AND CONTINGENCIES  
EQUITY    
Class A common stock, $0.01 par value; 35,000,000 shares authorized, 787,163 shares issued and outstanding as of July 31, 2022 and July 31, 2021, respectively 8 8
Class B common stock, $0.01 par value; 200,000,000 shares authorized, 23,712,449 issued and 23,687,964 outstanding as of July 31, 2022, and 16,947,066 issued and 16,936,864 outstanding as of July 31, 2021 237 169
Additional paid-in capital 262,023 159,136
Accumulated deficit (165,457) (40,799)
Accumulated other comprehensive loss related to unrealized loss on available-for-sale securities (63)
Accumulated other comprehensive income related to foreign currency translation adjustment 3,767 3,772
Total equity attributable to Rafael Holdings, Inc. 100,515 122,286
Noncontrolling interests (3,309) 14,418
TOTAL EQUITY 97,206 136,704
TOTAL LIABILITIES AND EQUITY $ 118,320 $ 154,055